S&P 500 Healthcare Sector SPDR (XLV)

Are Wall Street analysts favoring Moderna’s stock?

Despite Zoetis' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Despite underperforming the broader market over the past year, Wall Street analysts remain highly bullish on Abbott Laboratories' long-term outlook.

While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Johnson & Johnson has delivered a standout performance in 2025, outperforming both the broader market and the healthcare sector. Analysts continue to be fairly bullish on the stock’s trajectory.

As Baxter International has underperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

As Boston Scientific has outpaced the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Amgen stock has been underperforming the broader market over the past year, and analysts are adopting a cautiously bullish stance.

As CVS Health has significantly outpaced the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.